Venture • Life Science

Eight Roads Invests In Regenxbio

On January 1, 2013, private equity firm Eight Roads invested in life science company Regenxbio

Investment Context

This is Eight Roads’ 21st transaction in the Life Science sector.
This is Eight Roads’ 24th transaction in the United States.
This is Eight Roads’ 1st transaction in Maryland.

Investment Fate

Regenxbio went public in 2015.

Explore All 557 Venture Life Science Deals - Search the Database Free

Investment Summary
Date	January 1, 2013
Target	Regenxbio
Sector	Life Science
Investor(s)	Eight Roads
Deal Type	Venture

Target Company

Regenxbio

Rockville, Maryland, United States

Regenxbio is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Regenxbio’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio and its third-party NAV Technology licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas. Regenxbio was founded in 2008 and is based in Rockville, Maryland.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Investor Overview 1

Investor

Eight Roads

Investor Investor

Category	Private Equity Firm
Founded	1969
PE ASSETS	11.0B USD
Size	Mega
Type	Sector Focused

DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

Deal Context for Investor	#
Overall	59 of 293
Sector: Life Science	21 of 73
Type: Venture	46 of 266
State: Maryland	1 of 2
Country: United States	24 of 119
Year: 2013	4 of 14

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2013-01-01	Flywire Payments Boston, Massachusetts, United States Flywire Payments is a provider of global payment and receivables solutions, connecting over 1,400 businesses and institutions with their customers on six continents. The company processes billions in payments per year from 220 countries and territories, via bank transfer, credit card and e-wallet solutions, in over 120 different local currencies. Flywire’s scalable platform provides currency conversion at exchange rates that can offer significant savings when compared to home-market banks and credit card providers. The company also supports its clients with end-to-end customer support including multilingual servicing via phone, email, and chat, as well as 24/7 online payment tracking. Flywire Payments was founded in 2009 and is headquartered in Boston, Massachusetts with operations in London and Manchester, UK; Shanghai, China; Tokyo, Japan; Singapore; Sydney, Australia; and Valencia, Spain.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2013-01-01

Flywire Payments

Boston, Massachusetts, United States

Flywire Payments is a provider of global payment and receivables solutions, connecting over 1,400 businesses and institutions with their customers on six continents. The company processes billions in payments per year from 220 countries and territories, via bank transfer, credit card and e-wallet solutions, in over 120 different local currencies. Flywire’s scalable platform provides currency conversion at exchange rates that can offer significant savings when compared to home-market banks and credit card providers. The company also supports its clients with end-to-end customer support including multilingual servicing via phone, email, and chat, as well as 24/7 online payment tracking. Flywire Payments was founded in 2009 and is headquartered in Boston, Massachusetts with operations in London and Manchester, UK; Shanghai, China; Tokyo, Japan; Singapore; Sydney, Australia; and Valencia, Spain.

Buy

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2013-01-11	Richcore Lifesciences Bangalore, India Richcore Lifesciences is an innovation-driven company focused on development and manufacture of industrial enzymes that have global relevance. Richcore Lifesciences was founded in 2005 and is based in Bengaluru, India.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2013-01-11

Richcore Lifesciences

Bangalore, India

Richcore Lifesciences is an innovation-driven company focused on development and manufacture of industrial enzymes that have global relevance. Richcore Lifesciences was founded in 2005 and is based in Bengaluru, India.

Buy

Explore Related M&A Activity

Life Science M&A - Venture M&A Deals - Maryland M&A - United States M&A - 2013 M&A